PRLD
Prelude Therapeutics Inc
Next earnings Aug 12, 2026 · consensus $-0.24 EPS
Last earnings -3.3% on 2026-05-12
$4.38
▲ +6.83%$4.38▲ +409.01%
over 1Y
L $0.78EODHDH $5.52
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.8%
1W+1.4%
1M+5.3%
3M+43.6%
YTD+60.4%
1Y+409.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 73.4% YoY; but unprofitable (net margin -819.6%).
Prelude Therapeutics Inc shows $12.1M in FY2025 revenue (+73.4% YoY), a -819.6% net margin, and -145.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $7.00M | $12.1M |
| Gross profit | — | — | — | — | — |
| Operating income | -$114M | -$124M | -$132M | -$140M | -$105M |
| Net income | -$112M | -$115M | -$122M | -$127M | -$99.5M |
| Diluted EPS | -$2.43 | -$2.44 | -$2.02 | -$1.68 | -$1.29 |
| Net margin | — | — | — | -1816.8% | -819.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$241M
EV / EBITDA—
EV / Sales19.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-36.1%
FCF yield-20.4%
Quality & risk
ROIC (est.)-120.4%
Free cash flow-$56.4M
Total debt—
Net cash$35.3M
Altman Z-Score-6.40 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+14.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗8-KPeriod ending 2026-06-092026-06-10open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗4Period ending 2026-05-012026-05-04open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEFA14AFiling2026-04-29open ↗
Frequently asked
- Is Prelude Therapeutics Inc (PRLD) a buy?
- PRLD currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 73.4% YoY; but unprofitable (net margin -819.6%).
- What is Prelude Therapeutics Inc's quality score?
- PRLD scores 46.33333333333333/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001678660, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:55:21 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.